A new blood-based diagnostic test (IsoPSA) for prostate cancer that evaluates structural changes in prostate-specific antigen could reduce unnecessary biopsies and identify the right patients that ...
A phase 2 study of ibrutinib as neoadjuvant therapy in patients with localized prostate cancer. Predicted probability of csPCa at biopsy.
The impact of prostate cancer on outcomes of patients hospitalized with acute myocardial injury: A national representative sample. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.
CLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a pioneering, commercial-stage precision oncology company, announced today that the U.S. Food and Drug Administration (FDA) has approved the ...
CLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results